The Clinical Efficacy of Paliperidone and Perospirone in the Treatment of Male Schizophrenia Patients and Its Impact on Serum Prolactin Levels
Objective To compare the clinical efficacy and impact on serum prolactin levels of paliperidone and perospirone in the treatment of male schizophrenia patients.Methods Seventy male patients with schizophrenia who underwent treatment in Yichun Third People's Hospital from January 2020 to January 2023 were selected.According to the admission time,the study subjects were randomly divided into treatment group A and treatment group B,with 35 patients in each group.Treatment group A was treated with paliperidone,while treatment group B was treated with perospirone.Compare the clinical efficacy and impact on serum prolactin levels of paliperidone and perospirone in the treatment of male schizophrenia patients.Results After treatment,the PANSS scores and total scores of patients in both group decreased,compared with treatment group B,the PANSS scores in treatment group A were lower,and the difference was statistically significant(P<0.05).After treatment,compared with Group B,Group A had a higher incidence of weight gain and a lower incidence of inability to sit still,the difference was significant(P<0.05).After treatment,compared with before treatment,the prolactin levels in treatment group A were higher,and statistically significant differences were observed(P<0.05).Conclusion Both paliperidone and perospirone can effectively control mental disorders in male schizophrenics,greatly improving their mental state and symptoms,reducing the occurrence of adverse emotions such as anxiety and depression.The adverse reactions is low.Paliperidone has a stronger ability to improve positive and negative symptoms of antipsychotic diseases,but it is highly susceptible to increased body weight and prolactin expression.
NETL
NSTL
万方数据
